NCT00478257

Brief Summary

Patients treated with chemotherapy complain of poor sleep, fatigue and depression. In addition, chemotherapy disrupts the body's internal "biological clock", which may make sleep, fatigue and depression all worse. Women with breast cancer undergoing chemotherapy are not exposed to much bright light and this may also contribute to the disruption of their body clock, because bright light is necessary for a strong biological clock. One of the easiest ways to strengthen the biological clock is by increasing bright light exposure. The correct timing of the light exposure will help the women feel more alert during the day.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
39

participants targeted

Target at below P25 for not_applicable breast-cancer

Timeline
Completed

Started Nov 2005

Typical duration for not_applicable breast-cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2005

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

May 22, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 24, 2007

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2009

Completed
6.6 years until next milestone

Results Posted

Study results publicly available

June 16, 2016

Completed
Last Updated

February 6, 2019

Status Verified

January 1, 2019

Enrollment Period

4 years

First QC Date

May 22, 2007

Results QC Date

June 18, 2012

Last Update Submit

January 22, 2019

Conditions

Keywords

fatiguesleepquality of lifelightcancer

Outcome Measures

Primary Outcomes (1)

  • Fatigue

    The Short Form of the Multidimensional Fatigue Symptom Inventory (MFSI-sf) was used to measure fatigue. The range of possible score for each subscale is 0 to 24, and the range for total score is -24 to 96, with a higher score indicating more severe fatigue, except for the Vigor subscale, where larger score indicates less fatigue.

    four cycles of chemotherapy

Study Arms (2)

1 Active Bright White Light Treatment

ACTIVE COMPARATOR

Intervention: Bright white light, the intervention, was administered via a light box made by Litebook Inc for 30 minutes each morning during four cycles of chemotherapy

Device: bright white light

2 Comparator Red Light Treatment

ACTIVE COMPARATOR

Intervention: Dim red light, the intervention, was administered via a light box made by Litebook Inc for 30 minutes each morning during four cycles of chemotherapy

Device: comparator red light treatment

Interventions

Intervention: Bright white light administered for 30 minutes each morning

1 Active Bright White Light Treatment

dim red light administered for 30 minutes every morning

2 Comparator Red Light Treatment

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • stage I-III breast cancer
  • adjuvant or neoadjuvant anthracycline-based chemotherapy

You may not qualify if:

  • under age 18
  • pregnancy
  • metastatic or inoperable (including inflammatory) breast cancer
  • confounding underlying medical illnesses
  • history of mania
  • history of other axis-I psychiatric disorder
  • other physical or psychological impairments -

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Moores UCSD Cancer Center

San Diego, California, 92093, United States

Location

Related Publications (4)

  • Ancoli-Israel S, Rissling M, Neikrug A, Trofimenko V, Natarajan L, Parker BA, Lawton S, Desan P, Liu L. Light treatment prevents fatigue in women undergoing chemotherapy for breast cancer. Support Care Cancer. 2012 Jun;20(6):1211-9. doi: 10.1007/s00520-011-1203-z. Epub 2011 Jun 11.

  • Jeste N, Liu L, Rissling M, Trofimenko V, Natarajan L, Parker BA, Ancoli-Israel S. Prevention of quality-of-life deterioration with light therapy is associated with changes in fatigue in women with breast cancer undergoing chemotherapy. Qual Life Res. 2013 Aug;22(6):1239-44. doi: 10.1007/s11136-012-0243-2. Epub 2012 Aug 3.

  • Neikrug AB, Rissling M, Trofimenko V, Liu L, Natarajan L, Lawton S, Parker BA, Ancoli-Israel S. Bright light therapy protects women from circadian rhythm desynchronization during chemotherapy for breast cancer. Behav Sleep Med. 2012;10(3):202-16. doi: 10.1080/15402002.2011.634940.

  • Rissling M, Liu L, Youngstedt SD, Trofimenko V, Natarajan L, Neikrug AB, Jeste N, Parker BA, Ancoli-Israel S. Preventing Sleep Disruption With Bright Light Therapy During Chemotherapy for Breast Cancer: A Phase II Randomized Controlled Trial. Front Neurosci. 2022 Mar 9;16:815872. doi: 10.3389/fnins.2022.815872. eCollection 2022.

MeSH Terms

Conditions

Breast NeoplasmsFatigueNeoplasms

Interventions

Ultraviolet Therapy

Condition Hierarchy (Ancestors)

Neoplasms by SiteBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PhototherapyTherapeutics

Limitations and Caveats

Small sample size; only partial compliance data; light only administered in morning; only tested effect in patients with breast cancer.

Results Point of Contact

Title
Dr. Sonia Ancoli-Israel
Organization
UCSD

Study Officials

  • Sonia Ancoli-Israel, PhD

    University of California, San Diego

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

May 22, 2007

First Posted

May 24, 2007

Study Start

November 1, 2005

Primary Completion

November 1, 2009

Study Completion

November 1, 2009

Last Updated

February 6, 2019

Results First Posted

June 16, 2016

Record last verified: 2019-01

Locations